Mal-PEG4-Val-Cit-PAB-PNP is a maleimide-functionalized cleavable ADC linker with PEG spacer and valine-citrulline peptide for enzyme-triggered drug release in antibody-drug conjugates.
Structure of 2112738-09-5
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Mal-PEG4-Val-Cit-PAB-PNP is a specialized bioconjugation reagent designed for use in targeted drug delivery systems, including antibody-drug conjugates (ADCs) and other precision therapies. The compound incorporates a maleimide (Mal) group for conjugation to thiol-containing biomolecules such as peptides, antibodies, or proteins, a polyethylene glycol (PEG4) spacer for enhanced solubility and stability, and a Val-Cit-PAB-PNP (valine-citrulline-p-aminobenzyloxycarbonyl-p-nitrophenyl) linker. The PNP group facilitates the release of the drug payload upon enzymatic cleavage, making this compound ideal for controlled and selective drug delivery to disease sites.
One of the primary applications of Mal-PEG4-Val-Cit-PAB-PNP is in the development of antibody-drug conjugates (ADCs) for cancer therapy. The maleimide group enables conjugation with monoclonal antibodies, which target specific tumor antigens, while the PEG4 spacer enhances the pharmacokinetics of the conjugate by improving solubility and reducing immunogenicity. The Val-Cit-PAB-PNP linker is cleaved by tumor-specific proteases, allowing for the release of cytotoxic drugs directly at the tumor site. The PNP group facilitates controlled drug release, ensuring that the therapeutic agent is delivered selectively to cancer cells, minimizing systemic toxicity, and enhancing the overall efficacy of the treatment.
Mal-PEG4-Val-Cit-PAB-PNP is also utilized in the development of other targeted drug delivery systems, such as those for RNA-based therapies, small molecules, or gene therapies. The PEG4 spacer not only improves the solubility and stability of the conjugate but also prolongs its circulation time in the bloodstream, ensuring more efficient delivery to the target site. The cleavable linker ensures that the therapeutic agent is released at the disease site in response to enzymatic activity, offering precise control over drug release. This makes Mal-PEG4-Val-Cit-PAB-PNP ideal for designing personalized therapies, where drugs can be selectively delivered to tissues or organs that express specific biomarkers, such as tumors or infected tissues.
In addition to its role in drug delivery, Mal-PEG4-Val-Cit-PAB-PNP is also valuable in biomolecule labeling and protein conjugation applications. The maleimide group enables covalent attachment to thiol-containing molecules, while the PEG4 spacer ensures stability and solubility in aqueous solutions. The PNP group can be used for bioorthogonal reactions, allowing for precise labeling or tracking of biomolecules. This compound is particularly useful in proteomics, cell biology, and molecular imaging applications, where accurate biomolecule detection and analysis are required for understanding cellular processes, protein interactions, and disease mechanisms.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01679 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | |
BADC-00929 | Fmoc-D-Val-Cit-PAB | 1350456-65-3 | |
BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 | |
BADC-00968 | MC-Val-Cit-PAB | 159857-80-4 | |
BADC-00501 | Mc-Val-Cit-PABC-PNP | 159857-81-5 | |
BADC-00364 | Fmoc-Val-Cit-PAB | 159858-22-7 | |
BADC-01745 | MC-Val-Cit-PAB-NH-C2-NH-Boc | 1616727-22-0 | |
BADC-00610 | Mc-Val-Cit-PAB-Cl | 1639351-92-0 | |
BADC-01470 | MC-Val-Cit-PAB-dimethylDNA31 | 1639352-06-9 | |
BADC-00611 | MC-Val-Cit-PAB-clindamycin | 1639793-13-7 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.